Results 181 to 190 of about 6,340 (200)

Plecanatide, Nusinersen, and Obeticholic acid

Journal of the American Pharmacists Association, 2017
Daniel A, Hussar, Deborah K, Douglas
openaire   +2 more sources

Obeticholic-acid

Reactions Weekly, 2018
openaire   +2 more sources

Obeticholic Acid Impact on Quality of Life in Patients With Nonalcoholic Steatohepatitis: REGENERATE 18-Month Interim Analysis

Clinical Gastroenterology and Hepatology, 2022
Zobair M Younossi, Maria Stepanova, Quentin M Anstee   +2 more
exaly  

Is Obeticholic Acid the Solution to Nonalcoholic Steatohepatitis?

Gastroenterology, 2015
Vincent Wai-Sun, Wong, Grace Lai-Hung, Wong, Francis Ka-Leung, Chan   +2 more
openaire   +2 more sources

Obeticholic acid: towards first approval for NASH

The Lancet, 2019
Mohammed, Eslam, Rino, Alvani, Gamal, Shiha   +2 more
openaire   +2 more sources

Obeticholic-acid

Reactions Weekly, 2019
openaire   +1 more source

Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial

Lancet, The, 2015
Brent A Neuschwander-Tetri, Arun J Sanyal, Joel E Lavine   +2 more
exaly  

Obeticholic acid for the treatment of nonalcoholic steatohepatitis: Expectations and concerns

Metabolism, 2020
Stergios A, Polyzos, Jannis, Kountouras, Christos S, Mantzoros   +2 more
openaire   +2 more sources

Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial

Lancet, The, 2019
Zobair M Younossi, Quentin M Anstee, Zachary Goodman   +2 more
exaly  

Efficacy and Safety of the Farnesoid X Receptor Agonist Obeticholic Acid in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease

Gastroenterology, 2013
Arun J Sanyal, Hanns-Ulrich Marschall
exaly